SCHEMBL30141491

SCHEMBL30141491

COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 17/20 0.78
ERBB2 P04626 4/20 0.78
RIPK2 O43353 2/20 0.75
EPHB2 P29323 1/20 0.75
KDR P35968 5/20 0.73
RET P07949 2/20 0.73
ERBB4 Q15303 2/20 0.72
LCK P06239 4/20 0.72
FLT3 P36888 2/20 0.69
CHEK2 O96017 1/20 0.69
ROS1 P08922 1/20 0.69
AURKB Q96GD4 1/20 0.69
CLK4 Q9HAZ1 1/20 0.69
MKNK2 Q9HBH9 1/20 0.69
GAK O14976 1/20 0.67
STK10 O94804 1/20 0.67
JAK3 P52333 1/20 0.67
AAK1 Q2M2I8 1/20 0.67
Q6ZSR9 Q6ZSR9 1/20 0.67
SLK Q9H2G2 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL242224 1.00 EGFR (0.78) EGFRERBB2RIPK2EPHB2KDR
Hydrochloric Acid SCHEMBL8809813 0.99 EGFR (0.76) EGFRERBB2RIPK2EPHB2KDR
SCHEMBL8808387 0.95 EGFR (0.75) EGFRERBB2RIPK2EPHB2KDR
SCHEMBL30891782 0.92 EGFR (0.83) EGFRERBB2RIPK2EPHB2KDR
Trifluoroacetic Acid SCHEMBL20494312 0.91 EGFR (0.72) EGFRERBB2RIPK2EPHB2KDR
SCHEMBL15607659 0.91 EGFR (0.78) EGFRERBB2RIPK2EPHB2KDR
Hydrochloric Acid SCHEMBL8364042 0.91 EGFR (0.70) EGFRERBB2RIPK2EPHB2KDR
SCHEMBL1387156 0.90 EGFR (0.75) EGFRERBB2RIPK2EPHB2KDR
Hydrochloric Acid SCHEMBL8810888 0.89 EGFR (0.68) EGFRERBB2RIPK2EPHB2ERBB4
Hydrochloric Acid SCHEMBL8811182 0.89 EGFR (0.76) EGFRERBB2RIPK2EPHB2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118159647-A Method for producing cardiomyocyte layer, and use thereof 富士胶片株式会社 2024-06-07 CN disclosed
US-20240016840-A1 METHODS AND COMPOSITIONS FOR USE OF THERAPEUTIC T CELLS IN COMBINATION WITH KINASE INHIBITORS JUNO THERAPEUTICS, INC. (US) 2024-01-18 US disclosed
US-11590167-B2 Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors Juno Therapeutic, Inc. (US) 2023-02-28 US disclosed
WO-2023286772-A1 CARDIOMYOCYTE PRODUCTION METHOD 三菱ケミカル株式会社 2023-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240016840-A1 METHODS AND COMPOSITIONS FOR USE OF THERAPEUTIC T CELLS IN COMBINATION WITH KINASE INHIBITORS ITK, PBK, BMX EGFR 37/4885ERBB2 13/4885RIPK2 468/4885
US-11590167-B2 Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors ITK, PBK, BMX EGFR 30/4885ERBB2 11/4885RIPK2 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.